SAL0140

Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	SAL0140
Sponsor	Shenzhen Salubris Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SAL0140 CI brief — competitive landscape report
SAL0140 updates RSS · CI watch RSS
Shenzhen Salubris Pharmaceuticals Co., Ltd. portfolio CI